Numerous clinical and preclinical studies have explored the therapeutic potential of targeting the Mstn and/or Activin signaling pathways, primarily in the context of muscular dystrophies, reflecting growing interest in these factors as regulators of musculoskeletal health. This evidence concerns the gene INHBE and muscular dystrophy.